Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Trading 03-19 12:49:45 EDT

4.85

+0.07

+1.36%

High4.88	Low4.67	Vol502.11K
Open4.67	D1 Closing4.78	Amplitude4.39%
Mkt Cap312.84M	Tradable Cap263.63M	Total Shares64.57M
T/O2.40M	T/O Rate0.92%	Tradable Shares54.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.845,"timestamp":1773938972181,"preClose":4.78,"halted":0,"volume":502113,"delay":0,"changeRate":0.013598326359832531,"floatShares":54411779,"shares":64569967,"eps":-1.27295,"marketStatus":"Trading","change":0.065,"latestTime":"03-19 12:49:45 EDT","open":4.67,"high":4.88,"low":4.67,"amount":2395150.812159,"amplitude":0.043933,"askPrice":4.85,"askSize":229,"bidPrice":4.84,"bidSize":63,"shortable":3,"etf":0,"ttmEps":-1.27295,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773950400000},"marketStatusCode":2,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":4.78,"preHourTrading":{"tag":"盘前","latestPrice":4.7001,"preClose":4.78,"latestTime":"09:25 EDT","volume":1066,"amount":5060.7439636,"timestamp":1773926735551,"change":-0.0799,"changeRate":-0.016715,"amplitude":0.027176},"postHourTrading":{"tag":"盘后","latestPrice":4.78,"preClose":4.78,"latestTime":"19:53 EDT","volume":13536,"amount":64677.6453,"timestamp":1773878026919,"change":0,"changeRate":0,"amplitude":0.004184},"volumeRatio":0.842838,"impliedVol":0.2363,"impliedVolPercentile":0.0345},"requestUrl":"/m/hq/s/IMRX/wiki","defaultTab":"wiki","newsList":[{"id":"2620403692","title":"Immuneering to present atebimetinib ctDNA analysis at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403692","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403692?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:37","pubTimestamp":1773779850,"startTime":"0","endTime":"0","summary":"Immuneering will present a poster at the AACR Annual Meeting in San Diego, California, held April 17-22, 2026. The poster session is scheduled for April 20, 2026, from 9:00 AM to 12:00 PM ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8p2hZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2620401952","title":"Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401952","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401952?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779700,"startTime":"0","endTime":"0","summary":"NEW YORK, March  17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today ann","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257690/0/en/Immuneering-to-Present-Molecular-Data-at-2026-AACR-Annual-Meeting-from-Atebimetinib-Treated-Patients-Highlighting-Mechanism-Designed-to-Improve-Durability-and-Survival.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","BK4139","IMRX"],"gpt_icon":0},{"id":"2618003922","title":"Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618003922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618003922?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:35","pubTimestamp":1773250534,"startTime":"0","endTime":"0","summary":"In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Immuneering, with a price target of $12.00. Suvanna...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","IMRX"],"gpt_icon":0},{"id":"2618482640","title":"Immuneering price target lowered to $12 from $13 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2618482640","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618482640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:56","pubTimestamp":1773053794,"startTime":"0","endTime":"0","summary":"Piper Sandler lowered the firm’s price target on Immuneering (IMRX) to $12 from $13 and keeps an Overweight rating on the shares following the comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-price-target-lowered-to-12-from-13-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-price-target-lowered-to-12-from-13-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"gpt_icon":0},{"id":"2618684642","title":"Immuneering Price Target Maintained With a $11.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2618684642","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618684642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:01","pubTimestamp":1773050460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:01 ET (10:01 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2617163277","title":"BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2617163277","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617163277?lang=en_us&edition=fundamental","pubTime":"2026-03-07 02:48","pubTimestamp":1772822926,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL6N3ZU0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUV","PRSO","CAT","RIO.AU","ALOY","GPRO","RIO.UK","EDSA","WSR","DXST","SYNX","WTI","SLDB","CUBI","DAL","WAL","SCCO","GWRE","INGM","PRU","JEF","BHP.AU","OWLT","MEI","CCHH","GAP","DOW","APA","AAL","CF","FCX","IOT","BLK","ASPI","SKYQ","DAWN","ODFL","TER","UAL","BX","SWBI","KR","FANG","IMRX","AMPX"],"gpt_icon":1},{"id":"2617313176","title":"BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2617313176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617313176?lang=en_us&edition=fundamental","pubTime":"2026-03-06 23:58","pubTimestamp":1772812697,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners  Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL6N3ZU11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GAP","WAL","SLDB","CUBI","LUV","DXST","AALG","DAL","RIO.UK","SCCO","BHP.AU","DAWN","ELPW","PL","BLK","APA","PRSO","CF","FANG","AMPX","RIO.AU","WSR","MEI","SYNX","DOW","IOT","OWLT","BX","ALOY","IMRX","ASPI","SWBI","UAL","AAL","PMAX","XOMZ","CCHH","FCX","JEF","KR","CAT","INGM","ODFL","GWRE","PLU","MVLL","CIEN"],"gpt_icon":1},{"id":"2617330376","title":"BUZZ-U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2617330376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617330376?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:12","pubTimestamp":1772806362,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid BiosciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL6N3ZU0QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAT","IE00BN8TJ469.HKD","LU0187121727.USD","LU0300736492.USD","BK4581","LU0957808578.USD","LU0203347892.USD","LU1116320737.USD","LU2458330169.SGD","LU1791807156.HKD","SG9999002224.SGD","LU1839511570.USD","LU2505996509.AUD","LU1496350171.SGD","LU0942090050.USD","LU0792757196.USD","LU1582987597.SGD","LU2592432038.USD","LU2473716301.USD","LU1150488135.SGD","LU0476273544.USD","LU0266512127.USD","LU2272731600.USD","IE00BLSP4239.USD","SG9999000418.SGD","IMRX","BK4213","LU0878866978.SGD","LU1066053197.SGD","LU1668664300.SGD","LU1732799900.SGD","LU1974910355.USD","LU2543165471.USD","LU2087621335.USD","LU1489326972.SGD","LU1430597077.USD","LU0154236417.USD","IE00BMPRXR70.SGD","LU0433182093.SGD","LU0251131958.USD","LU2098885051.SGD","LU2357305700.SGD","LU2430703095.HKD","LU0630314457.HKD","SG9999001440.SGD","LU0098860793.USD","LU0417517546.SGD","SG9999014575.USD","BK4149","LU2272731865.HKD","LU0081259029.USD","LU1861220033.SGD","IE00BWXC8680.SGD","LU1674673691.USD","LU0278409577.USD","MVLL","BK4201","BK4534","DOW","XOMZ","LU2498475776.HKD","LU1169590202.USD","LU0106831901.USD","LU1582986433.USD","BK4543","LU1150488218.USD","LU2462611646.USD","SG9999015341.SGD","LU0985489474.SGD","LU0234572021.USD","SG9999002521.SGD","IE00B3CCJ963.GBP","BK4094","LU1718418525.SGD","LU0320765646.SGD","APA","LU1720051108.HKD","LU1823568750.SGD","LU1989764664.SGD","LU0127658192.USD","BK4190","BK4563","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0868494708.USD","LU1548497426.USD","LU1267930813.SGD","MRVU","LU1496350502.SGD","LU0061475181.USD","LU2272731782.SGD","LU0963586101.USD","BK4141","BK4592","LU1316542783.SGD","LU2322448957.HKD","SG9999014542.SGD","LU1169589451.USD","LU0256863811.USD","LU0640476718.USD","BK4023","LU0444973449.USD","LU1642822529.SGD","LU2264538146.SGD","IE00B2Q91V27.USD","LU2360107168.USD","LU1582986359.USD","IE00BD6J9T35.USD","BK4532","LU1732800096.USD","LU0345780950.USD","BK4597","LU1894683348.USD","IE0002270589.USD","LU1084165304.USD","BK4589","LU2129689431.USD","LU0203345920.USD","LU0122376428.USD","LU0795875086.SGD","LU2129689514.USD","LU0251142724.SGD","LU0170899867.USD","LU1992135472.HKD","LU2430703251.USD","IE00B7SZLL34.SGD","LU0912757837.SGD","BK4566","IE000M9KFDE8.USD","LU1582987324.SGD","LU0642271901.SGD","LU2129689605.HKD","LU0742534661.SGD","LU0612318971.USD","BK4515","CUBI","LU0795875169.SGD","LU1917777945.USD","LU0368265418.SGD","BK4585","LU0654597011.USD","FANG","LU1720051017.SGD","LU1929549753.HKD","BK4127","LU1988902786.USD","LU0787776722.HKD","LU1066051498.USD","LU2602419157.SGD","BK4559","IE00BFXG1179.USD","LU0889566641.SGD","LU2458330243.SGD","LU2347655156.SGD","ALOY","SG9999014567.USD","BK4140","LU2237438978.USD","IE00BMPRXN33.USD","LU0070302665.USD","LU1674673428.USD","BK4211","SG9999002232.USD","BK4520","LU1116320901.HKD","BK4516","LU0266512473.USD","LU0345770308.USD","LU1883866441.USD","LU2106854487.HKD","LU0068578508.USD","SWBI","LU0265550359.USD","LU1989764748.USD","LU2430703178.SGD","LU2381873111.SGD","IE00BBT3K403.USD","LU0345770993.USD","LU0612318385.USD","XOMX","LU0265550946.USD","LU1074936037.SGD","LU1894683264.USD","BK4604","INGM","LU1046421795.USD","LU2505996681.GBP","GAP","BK4539","LU0274383776.USD","LU0456854461.SGD","LU0788109394.HKD","LU0444971666.USD","LU0070217475.USD","LU1815336760.USD","LU2089985449.USD","LU2322448791.USD","LU1162221912.USD","XOMO","IE00B1XK9C88.USD","LU1119994496.HKD","LU1852331112.SGD","LU1261432733.SGD","LU2133065610.SGD","LU1303367103.USD","SLDB","WAL","BK4605","BK4588","LU0149725797.USD","LU2023250504.SGD","LU0345781412.USD","LU2931357623.SGD","SG9999015358.SGD","LU0786609619.USD","LU2290526834.HKD","LU1280957306.USD","IE0034235303.USD","LU0300736062.USD","BK4139","LU2244417387.USD","LU0208291251.USD","LU0048573561.USD","BK4090","BK4570","IE00BKDWB100.SGD","JEF","SG9999014559.SGD","LU0056508442.USD","LU0466842654.USD","LU0868494617.USD","LU1992135399.USD","GWRE","LU0256331488.USD","LU1064131342.USD","LU1861215975.USD","LU0683600562.USD","LU1778281490.HKD","LU1235294995.USD","IE00BGHQF524.EUR","LU0320765489.SGD","BK4550","IE00BLSP4452.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2617638293","title":"Shares of Immuneering Down 1.8% Premarket After Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617638293?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:34","pubTimestamp":1772804073,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL4N3ZU14D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMRX","BK4539","BK4563"],"gpt_icon":0},{"id":"2617638673","title":"BUZZ-Immuneering rises as quarterly loss comes in below estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617638673?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:19","pubTimestamp":1772803171,"startTime":"0","endTime":"0","summary":"BUZZ-Immuneering rises as quarterly loss comes in below estimates** Shares of therapy developer Immuneering IMRX.O rise 2.6% to $5.01 premarket** Co reports Q4 adj. loss of 18 cents/shr vs analysts’ average estimate of 31 cents/shr – data compiled by LSEG** Co says cash runway expected to fund operations into 2029** IMRX says expanded pancreatic cancer cohort data on track for 1H 2026** Dosing in midstage trial of cancer drugs atebimetinib and Libtayo in lung cancer expected in 2H 2026, per co** Shares up ~199% in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL4N3ZU134:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"2617680155","title":"Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680155","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680155?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:56","pubTimestamp":1772801774,"startTime":"0","endTime":"0","summary":"Immuneering posts smallerthanexpected Q4 loss on reduced R&D costsOverviewOncology company's Q4 loss per share beat analyst expectationsNet loss for Q4 beat analyst estimatesCompany ended 2025 with $2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL1N3ZU0JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0},{"id":"2617868022","title":"Immuneering reports Q4 EPS (18), consensus (31c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617868022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617868022?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:52","pubTimestamp":1772801549,"startTime":"0","endTime":"0","summary":"“2025 was a transformative year for Immuneering (IMRX). We reported 64% overall survival at 12 months in first-line pancreatic cancer patients trea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q4-eps-18-consensus-31c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q4-eps-18-consensus-31c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"gpt_icon":0},{"id":"2617802036","title":"Immuneering sees cash runway into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2617802036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617802036?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:52","pubTimestamp":1772801530,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities as of December 31, 2025 were $217.0 million, compared with $36.1 million as of December 31, 2024. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-sees-cash-runway-into-2029-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-sees-cash-runway-into-2029-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4539","IMRX","BK4139"],"gpt_icon":0},{"id":"2617968098","title":"Immuneering’s IMRX Q4 R&D expenses fall 37.7% to USD 9.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617968098","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617968098?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:50","pubTimestamp":1772801440,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL16tcDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2617680501","title":"Immuneering Q4 EPS $(0.18) Beats $(0.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680501","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680501?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:48","pubTimestamp":1772801323,"startTime":"0","endTime":"0","summary":"Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 42.31 percent. This is a 68.97 percent increase over losses of $(0.58) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51092747/immuneering-q4-eps-0-18-beats-0-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2617868054","title":"Immuneering Corp - Expects Cash Runway to Fund Operations Into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2617868054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617868054?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nPLX264CB6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2617805276","title":"Immuneering Corp - Dosing in Phase 2 Trial of Atebimetinib + Libtayo in Nsclc Expected in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617805276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617805276?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nPLX264CB6:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"2617680594","title":"Immuneering Corporation Q4 EPS USD -0.18 VS. Ibes Estimate USD -0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680594","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680594?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nPLX264CB6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2617680543","title":"Immuneering Corp - on Track for Expanded Pancreatic Cancer Cohort Data Readout in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680543?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nPLX264CB6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4139","BK4539"],"gpt_icon":0},{"id":"2617805916","title":"Press Release: Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617805916","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617805916?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":"- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 -. - Dosing in Phase 2 trial of atebimetinib + Libtayo in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 -. - Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 -. NEW YORK, March 06, 2026  -- Immuneering Corporation , a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4022","BK4139","EMA","BK4563","IMRX","BK4097","BK4232","BK4539","OS","R"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.154},{"period":"1month","weight":-0.0304},{"period":"3month","weight":-0.157},{"period":"6month","weight":-0.4838},{"period":"1year","weight":1.8452},{"period":"ytd","weight":-0.2736}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.2,"avgChangeRate":0.039415},{"month":4,"riseRate":0.25,"avgChangeRate":-0.2067},{"month":5,"riseRate":0.25,"avgChangeRate":0.005771},{"month":6,"riseRate":0.75,"avgChangeRate":0.3519},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction